

PROGRESS IN NEUROSCIENCE PINS



Seminar Series of the
Brain & Mind Research Institute
Weill Cornell Medical College (WCMC)
&

The Graduate Program in Neuroscience of
WCMC and Sloan Kettering Institute

Thursday, 3/19/15, 4 PM, coffee at 3:45 PM

**** A-250 ****

“Drug Discovery and Development Changes”

Michael Foley, Ph.D.

Sanders Director, Tri-Institutional Discovery Institute

Research Description:



Michael A. Foley, a renowned chemist and entrepreneur, leads the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) — an innovative partnership recently formed by Weill Cornell Medical College, Memorial Sloan Kettering and The Rockefeller University to speed drug discovery.

Dr. Foley, who brings 25 years of industry and academic experience to Tri-I TDI, is the scientific co-founder of four companies and one academic institute and has placed 12 drugs into clinical development. He was most recently the Director of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. Previously, he worked at two major pharmaceutical companies, Bristol-Myers Squibb and GlaxoSmithKline.

Launched in October, the Tri-I TDI was designed to accelerate the development of biomedical research findings into innovative treatments for people with various diseases, including cancer. Under Dr. Foley's leadership, it will support investigators at the three member institutions during the early stages of drug discovery — a phase during which many promising ideas currently stall due to the lack of research funding.

The institute leverages institutional centers and facilities on the three campuses, including the Experimental Therapeutics Center and Technology Development Fund at Memorial Sloan Kettering, the Abby and Howard P. Milstein Program in Medicinal Chemistry at Weill Cornell Medical College, and the High-Throughput Screening Resource Center at The Rockefeller University. Projects range from addressing the developing world's most serious and deadly diseases — from Alzheimer's disease, cancer, HIV, heart disease, and obesity, to tuberculosis and malaria — to tackling neglected or “orphan” diseases that afflict small numbers of people.

Recent Relevant Publications

- *Nature Reviews Drug Discovery*, August 2013, page 581
- *J. Org. Chem.*, **2012**, 77 (17), pp 7187–7211
- *Nature Chemistry* 6, 484–491 (2014)



Weill Cornell Medical College

